SARS-CoV-2 in an Immunocompromised Host This letter describes an immunocompromised
patient who had persistent infection with SARS-CoV-2 over a period of months, despite …

… Panels B through E show Kaplan–Meier survival curves for the time from an initial positive
PCR assay to a negative PCR assay, according to viral variant (Panel B) and vaccination …

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
but the risk of the virus evolving to escape them remains unclear. Here we map …

The SARS-CoV-2 Omicron variant is more immune evasive and less virulent than other
major viral variants that have so far been recognized 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 – 12 . …

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following
nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log 10 copies/mL) were detected …

Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics. Safety,
antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized controlled trial …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain
insight into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in …

Isolation guidelines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are
largely derived from data collected prior to the emergence of the delta variant. We followed a …

SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have
been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 …

Background Data on pediatric coronavirus disease 2019 (COVID-19) has lagged behind
adults throughout the pandemic. An understanding of severe acute respiratory syndrome …